CVS Health Co. (NYSE:CVS) Stock Position Decreased by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC reduced its position in CVS Health Co. (NYSE:CVS - Free Report) by 43.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,663 shares of the pharmacy operator's stock after selling 5,195 shares during the period. Dorsey & Whitney Trust CO LLC's holdings in CVS Health were worth $299,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. MidAtlantic Capital Management Inc. acquired a new stake in CVS Health in the third quarter valued at $25,000. Ridgewood Investments LLC raised its stake in shares of CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after purchasing an additional 450 shares in the last quarter. Stonebridge Financial Group LLC bought a new position in shares of CVS Health during the fourth quarter worth about $28,000. Legacy Investment Solutions LLC acquired a new position in CVS Health in the third quarter worth about $31,000. Finally, Financial Perspectives Inc increased its holdings in CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after buying an additional 466 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Price Performance

CVS traded down $0.16 during trading on Wednesday, reaching $64.82. The stock had a trading volume of 3,101,233 shares, compared to its average volume of 11,595,820. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $80.75. The firm has a market capitalization of $81.73 billion, a price-to-earnings ratio of 17.72, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53. The stock has a 50 day moving average of $57.24 and a two-hundred day moving average of $56.83. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

Remove Ads

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, equities analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.10%. CVS Health's dividend payout ratio (DPR) is 72.68%.

Insider Transactions at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now directly owns 39,356 shares of the company's stock, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.24% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Piper Sandler decreased their target price on CVS Health from $72.00 to $64.00 and set an "overweight" rating for the company in a research report on Monday, November 25th. Deutsche Bank Aktiengesellschaft raised shares of CVS Health from a "hold" rating to a "buy" rating and set a $66.00 target price on the stock in a report on Tuesday, December 3rd. Barclays lifted their price target on shares of CVS Health from $71.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Evercore ISI increased their price objective on shares of CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Monday, January 27th. Finally, Wells Fargo & Company increased their price target on CVS Health from $68.00 to $73.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $69.83.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.